Influenza A virus H5N1 neuraminidase (NA) (NA)

The H5N1 influenza A virus neuraminidase (NA) is a critical surface glycoprotein and enzyme essential for the viral life cycle (UniProt: P0C6Q6). Its primary biological function is to catalyze the cleavage of terminal sialic acid residues from host cell receptors and viral glycoproteins, which facilitates the release of progeny virions from infected cells and prevents viral self-aggregation (PubMed: 22226115). Beyond viral egress, NA also aids in the movement of the virus through the mucus of the respiratory tract by degrading sialic acid-containing mucins (PubMed: 11706212). In the context of H5N1, a highly pathogenic avian influenza strain, NA is a primary target for both therapeutic intervention and vaccine development. Small molecule inhibitors like oseltamivir and zanamivir target the conserved active site of the enzyme to halt viral spread (PubChem: CID 65028). Furthermore, the protein contains multiple antigenic epitopes that are the focus of research into broadly neutralizing antibodies and next-generation vaccines aimed at providing cross-protective immunity against evolving influenza strains (PubMed: 30104417). These epitopes are located primarily on the globular head of the NA tetramer and are subject to antigenic drift, which can lead to reduced vaccine efficacy and the emergence of resistant strains.

Other names

NeuraminidaseSialidaseN1 neuraminidaseExo-alpha-sialidaseH5N1 NAH5N1 influenza A virus neuraminidase protein – multiple antigenic epitopes

Neuraminidase inhibitors block the enzyme's active site, preventing the cleavage of terminal sialic acid residues from host cell receptors and viral glycoproteins, which traps progeny virions on the host cell surface (PubMed: 11706212).